Wall Street has high hopes for this mid-cap biotech in the coming year.
News & Analysis: Sarepta Therapeutics
The FDA's approval of a second Duchenne muscular dystrophy drug brings Sarepta one step closer to market leadership.
Sarepta scored a surprise regulatory win yesterday.
These dirt cheap healthcare stocks could be poised for a major upswing in 2020.
BioMarin and Sarepta Therapeutics should be top growth plays in the next decade.
SRPT earnings call for the period ending September 30, 2019.
The biotech topped Wall Street's top- and bottom-line estimates and raised its full-year revenue guidance.
With stock valuations down and out, the timing may be ripe for pharma and big biotech companies to start bargain hunting.
The stock continued a slide that began in August, but shares have started heading higher again in October on the heels of promising clinical data.
Find out which of these stocks rose following a big strategic move.